Amyotrophic Lateral Sclerosis (ALS)News & Research
14 curated articles for Amyotrophic Lateral Sclerosis (ALS) — FDA updates, peer-reviewed research, clinical-trial milestones, and sponsor press releases. Sorted newest-first.
- Muscle & nerve May 4, 2026
Integrating Serum Neurofilament Light Chain Into Amyotrophic Lateral Sclerosis Diagnostic Criteria.
Serum neurofilament light chain (NfL) is a promising diagnostic biomarker for differentiating amyotrophic lateral sclerosis (ALS) from clinical mimics. This study assessed the utility of integrating serum NfL into current diagnostic criteria to enhance diagnostic certainty in patients with a provisi...
Why it matters: Recent peer-reviewed research on Amyotrophic Lateral Sclerosis (ALS) that may be relevant for patients and caregivers.
- Genes May 4, 2026
Gene Targeted Therapies for Neurodegenerative Disorders: Strategies and Implications in ALS and SMA.
Advances in technology have provided a better understanding of the genetic basis of neurodegenerative disorders and their underlying molecular pathophysiology. However, treating these disorders with conventional strategies is a major challenge. The approval of gene targeted therapy for spinal muscul...
Why it matters: Recent peer-reviewed research on Amyotrophic Lateral Sclerosis (ALS) that may be relevant for patients and caregivers.
- Molecular neurobiology May 3, 2026
miRNAs in Amyotrophic Lateral Sclerosis: Tiny Molecules, Tremendous Impact.
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disorder distinguished by progressive motor neuron degeneration, with diverse clinical manifestations and complex genetic and environmental triggers. The variability in disease progression underscores the necessity for tailored diagnos...
Why it matters: Recent peer-reviewed research on Amyotrophic Lateral Sclerosis (ALS) that may be relevant for patients and caregivers.
- Brain research bulletin May 2, 2026
Abnormal cortical hierarchy revealed by gradient dysfunction in patients with definite amyotrophic lateral sclerosis.
Cortical multisystem dysfunction in amyotrophic lateral sclerosis (ALS) has been investigated, but disruptions in unimodal-to-transmodal cortical hierarchy remained unexplored. We identified cortical hierarchy abnormalities using functional connectivity gradient (FCG) analysis and evaluated their cl...
Why it matters: Recent peer-reviewed research on Amyotrophic Lateral Sclerosis (ALS) that may be relevant for patients and caregivers.
- Frontiers in neurology Apr 17, 2026
The effect of statins on the survival of patients with amyotrophic lateral sclerosis: a meta-analysis.
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease with limited disease-modifying therapies and a poor overall prognosis. Statins, are commonly used for dyslipidemia, and have been proposed to exert cholesterol-independent actions including anti-inflammatory and potential...
Why it matters: Recent peer-reviewed research on Amyotrophic Lateral Sclerosis (ALS) that may be relevant for patients and caregivers.
- Nature genetics Apr 15, 2026
Large-scale exome analyses reveal new rare variant contributions in amyotrophic lateral sclerosis.
Amyotrophic lateral sclerosis (ALS) is a heritable disorder where rare variants with low-to-moderate penetrance are thought to dominate genetic risk. To identify such rare variants, we harmonized and analyzed exome data from 22 cohorts, totaling 17,919 individuals with ALS and 200,703 controls acros...
Why it matters: Recent peer-reviewed research on Amyotrophic Lateral Sclerosis (ALS) that may be relevant for patients and caregivers.
- European journal of neurology Apr 6, 2026
Mortality From Amyotrophic Lateral Sclerosis in Finland 1987-2022.
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease. We assessed changes in the mortality from ALS in Finland from 1987 to 2022. Numbers of deaths caused by ALS (ICD-10 code G12.2) and population sizes by sex, age group, and year were obtained from Statistics Finland. Crude and ...
Why it matters: Recent peer-reviewed research on Amyotrophic Lateral Sclerosis (ALS) that may be relevant for patients and caregivers.
- International journal of molecular sciences Mar 28, 2026
Review of the Pathology of Muscle in Amyotrophic Lateral Sclerosis.
In amyotrophic lateral sclerosis (ALS), a central event is the withdrawal of the motor nerve terminal from its target muscle. Whether this defect is driven by faults in the motor neuron or faults that originate within the muscle remains an area of investigation. In this review, we focus on the patho...
Why it matters: Recent peer-reviewed research on Amyotrophic Lateral Sclerosis (ALS) that may be relevant for patients and caregivers.
- bioRxiv : the preprint server for biology Mar 11, 2026
cGAS inhibition delays TDP-43-driven ALS Pathogenesis.
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disorder marked by motor neuron loss and cytoplasmic mislocalization of TAR DNA-binding protein 43 (TDP-43), a key regulator of RNA splicing. However, the upstream modulators of this process remain poorly defined. Here we identify cycl...
Why it matters: Recent peer-reviewed research on Amyotrophic Lateral Sclerosis (ALS) that may be relevant for patients and caregivers.
- The Journal of neuroscience : the official journal of the Society for Neuroscience Mar 11, 2026
ALS and Huntington Disease: Unraveling the Connections between TDP-43 and Huntingtin.
Amyotrophic lateral sclerosis (ALS) and Huntington disease (HD) are lethal neurodegenerative diseases affecting motor function. Though their etiology and pathology are distinct, recent evidence suggests commonalities between TAR DNA-binding protein (TDP-43), which is associated with 97% of ALS cases...
Why it matters: Recent peer-reviewed research on Amyotrophic Lateral Sclerosis (ALS) that may be relevant for patients and caregivers.
- Nucleic acids research Mar 7, 2026
FUS is an N1- and N6-methyladenosine-binding protein.
Nucleotide repeat expansions contribute to a number of neurological disorders. Mutations and augmented expression in fused in sarcoma (FUS) can result in amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD). Here we reveal that FUS is an N1- and N6-methyladenosine (m1A- a...
Why it matters: Recent peer-reviewed research on Amyotrophic Lateral Sclerosis (ALS) that may be relevant for patients and caregivers.
- Neuron Feb 19, 2026
TDP-43 dysfunction compromises UPF1-dependent mRNA metabolism in ALS.
Up-frameshift protein 1 (UPF1)-mediated mRNA decay maintains transcriptome integrity and cellular homeostasis. However, its role in amyotrophic lateral sclerosis (ALS), a neurodegenerative disease characterized by TAR DNA-binding protein 43 (TDP-43) pathology and disrupted mRNA metabolism in motor n...
Why it matters: Recent peer-reviewed research on Amyotrophic Lateral Sclerosis (ALS) that may be relevant for patients and caregivers.
- Med (New York, N.Y.) Feb 14, 2026
IsomiR utility in amyotrophic lateral sclerosis prognostication.
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease characterized by progressive motor neuron loss. IsomiRs are microRNA (miRNA) isoforms that arise from alternative processing or editing events during miRNA biogenesis. While isomiRs may carry distinct biological and clinical re...
Why it matters: Recent peer-reviewed research on Amyotrophic Lateral Sclerosis (ALS) that may be relevant for patients and caregivers.
- Brain : a journal of neurology Feb 7, 2026
Genotype-specific interferon signatures in amyotrophic lateral sclerosis relate to disease severity.
Innate immune signalling pathways are hyperactivated in the CNS of patients with amyotrophic lateral sclerosis (ALS), as well as in preclinical models with diverse causative backgrounds including TDP-43, SOD1 and C9orf72 mutations. This raises an important question of whether these pathways are key ...
Why it matters: Recent peer-reviewed research on Amyotrophic Lateral Sclerosis (ALS) that may be relevant for patients and caregivers.
More on Amyotrophic Lateral Sclerosis (ALS)
Articles aggregated from peer-reviewed journals (PubMed), sponsor press releases, SEC 8-K filings, and FDA announcements. Original-source links are preserved on each article page. Editorial tags (Breaking / Notable / Update) reflect UniteRare's curation-time priority assessment.